Retinal fluid-free months impacts outcomes in nAMD after anti-VEGF therapy
A positive association between the total number of fluid-free months after loading and visual and anatomic outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (anti-VEGF) therapy was reported in a new study. This association was present, regardless of the type of fluid.
In this post-hoc analysis of pooled patient-level data from the brolucizumab 6 mg (n = 718) and aflibercept 2 mg (n = 715) arms of the HAWK and HARRIER randomized clinical trials, were collected from Weeks 12 to 96 to determine characteristics of fluid-free visits.
The best visual and anatomical outcomes at Week 96 were from patients who had 15 to 21 fluid-free visits and those who had 22 fluid-free visits and were always dry. These patients also had the lowest variability in retinal thickness over time.
The worst visual and anatomical outcomes were from patients who had no fluid-free visits and were never dry and those who had 1 to 7 fluid-free visits.
Eichenbaum D, Brown DM, Ip M, et al. Impact of retinal fluid-free months on outcomes in nAMD: a treatment agnostic analysis of the HAWK and HARRIER studies. Retina. 2022;doi: 10.1097/IAE.0000000000003699. Epub ahead of print. PMID: 36705252.